StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for WVE yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $6.79 | $6.77 | -0.29% | 4.2M |
| 05-18 | $6.77 | $6.40 | -5.47% | 6.6M |
| 05-19 | $6.22 | $6.14 | -1.29% | 8.1M |
| 05-20 | $6.25 | $6.19 | -0.96% | 4.6M |
| 05-21 | $6.15 | $6.42 | +4.39% | 3.7M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q2 2025 2025-06-30 | Q1 2025 2025-03-31 |
|---|---|---|---|---|
Revenue | $38.25M | $42.73M | $17.87M | $9.18M |
Operating Income | $-31.30M | $-215.38M | $-102.56M | $-49.80M |
Net Income | $-26.09M | $-204.38M | $-50.47M | $-46.88M |
EPS (Diluted) | $-0.13 | $-1.21 | $-0.60 | $-0.29 |
Total Assets | $583.54M | $638.50M | $252.35M | $288.34M |
Total Liabilities | $71.81M | $112.27M | $105.22M | $108.67M |
Cash & Equivalents | $544.59M | $602.07M | $208.48M | $243.07M |
Free Cash Flow OCF − CapEx | $-59.99M | $-188.21M | $-109.52M | $-63.20M |
Shares Outstanding | 192.34M | 187.66M | 155.67M | 154.09M |
WVE is in the extended universe. We surface dollar-volume + price-change percentiles for every US-listed name, but the full 6-factor DNA breakdown (momentum, news, sentiment, flow, relative strength) is only computed on the curated 1137-name primary list.
DNA analysis is not available for this ticker.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.